These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 37805421

  • 1. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N, Zhao QN, Yuan Q, Zhu BL, Wu W.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep 20; 41(9):641-647. PubMed ID: 37805421
    [Abstract] [Full Text] [Related]

  • 2. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
    Lin P, Zhao Y, Li X, Liang Z.
    Comb Chem High Throughput Screen; 2022 Sep 20; 25(9):1498-1506. PubMed ID: 34238152
    [Abstract] [Full Text] [Related]

  • 3. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    Reardon ES, Shukla V, Xi S, Gara SK, Liu Y, Straughan D, Zhang M, Hong JA, Payabyab EC, Kumari A, Richards WG, De Rienzo A, Hassan R, Miettinen M, Xi L, Raffeld M, Uechi LT, Li X, Wang R, Chen H, Hoang CD, Bueno R, Schrump DS.
    J Thorac Oncol; 2021 Jan 20; 16(1):89-103. PubMed ID: 32927122
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2019 Apr 20; 130():187-193. PubMed ID: 30885343
    [Abstract] [Full Text] [Related]

  • 9. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y, Huang W, Zhang L, Wang H.
    Front Endocrinol (Lausanne); 2022 Apr 20; 13():1056152. PubMed ID: 36523602
    [Abstract] [Full Text] [Related]

  • 10. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, Sato Y, Katsura H, Kanzaki M, Kondo M, Tagaya E.
    BMC Cancer; 2023 Dec 07; 23(1):1206. PubMed ID: 38062416
    [Abstract] [Full Text] [Related]

  • 11. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.
    J Thorac Oncol; 2013 Nov 07; 8(11):1389-95. PubMed ID: 24084442
    [Abstract] [Full Text] [Related]

  • 12. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W, Wang XM, Liu RA, Xiong W, Zhang YP.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr 20; 42(4):258-267. PubMed ID: 38677988
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.
    J Pathol; 2015 Oct 20; 237(2):203-14. PubMed ID: 26011651
    [Abstract] [Full Text] [Related]

  • 15. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M, Yu M, Zhu LJ, Yuan XY, Zhang X.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb 20; 39(2):91-98. PubMed ID: 33691361
    [Abstract] [Full Text] [Related]

  • 16. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan 20; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 17. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.
    J Thorac Oncol; 2018 Jan 20; 13(1):124-133. PubMed ID: 29079455
    [Abstract] [Full Text] [Related]

  • 18. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M, Trapani D, Ravn J, Sørensen JB, Andersen CB, Grauslund M, Santoni-Rugiu E.
    Anticancer Res; 2015 Nov 20; 35(11):6223-9. PubMed ID: 26504055
    [Abstract] [Full Text] [Related]

  • 19. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A, Bonilla DA, Ramirez CM, Escobar-Díaz FA, Combita AL, Forero DA, Orozco C.
    Biochem Genet; 2024 Feb 20; 62(1):352-370. PubMed ID: 37347449
    [Abstract] [Full Text] [Related]

  • 20. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
    Du X, Li X, Zhang B, Hao Z, Gao Y, Jiang X, Yang Z, Chen Y.
    Ann Diagn Pathol; 2023 Aug 20; 65():152155. PubMed ID: 37172528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.